Literature DB >> 1335364

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

L Chen1, S Ashe, W A Brady, I Hellström, K E Hellström, J A Ledbetter, P McGowan, P S Linsley.   

Abstract

Interaction of the B7 molecule on antigen-presenting cells with its receptors CD28 and CTLA-4 on T cells provides costimulatory signals for T cell activation. We have studied the effects of B7 on antitumor immunity to a murine melanoma that expresses a rejection antigen associated with the E7 gene product of human papillomavirus 16. While this E7+ tumor grows progressively in immunocompetent hosts, cotransfection of its cells with B7 led to tumor regression by a B7-dependent immune response mediated by CD8+ cytolytic T lymphocytes. The immune response induced by E7+B7+ tumor cells also caused regression of E7+B7- tumors at distant sites and was curative for established E7+B7- micrometastases. Our findings suggest that increasing T cell costimulation through the CD28 and CTLA-4 receptors may have therapeutic usefulness for generating immunity against tumors expressing viral antigens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335364     DOI: 10.1016/s0092-8674(05)80059-5

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  204 in total

1.  Enhancement of cALL immunogenicity by co-culture with a CD154 expressing 293 cell line.

Authors:  A J Lee; C Haworth; R M Hutchinson; R Patel; R Carter; R F James
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

2.  Gene gun transfection of human glioma and melanoma cell lines with genes encoding human IL-12 and GM-CSF.

Authors:  A L Gainer; I F Parney; K C Petruk; J F Elliott
Journal:  J Neurooncol       Date:  2000-03       Impact factor: 4.130

3.  Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.

Authors:  E D Kwon; A A Hurwitz; B A Foster; C Madias; A L Feldhaus; N M Greenberg; M B Burg; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

4.  Cellular but not humoral immune responses generated by vaccination with dendritic cells protect mice against leukaemia.

Authors:  B M Colombo; R Lacave; C Pioche-Durieu; C Masurier; F M Lemoine; M Guigon; D Klatzmann
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

5.  Immunoglobulin fusion proteins as a tool for evaluation of T-cell costimulatory molecules.

Authors:  Andrei I Chapoval; Gefeng Zhu; Lieping Chen
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

6.  A role for sialoadhesin-positive tissue macrophages in host resistance to lymphoma metastasis in vivo.

Authors:  V Umansky; P Beckhove; M Rocha; A Krüger; P R Crocker; V Schirrmacher
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

7.  Poor induction of interleukin-2 receptor expression on CD8bright+ cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAb.

Authors:  R A Janssen; A A Heijn; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

8.  Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.

Authors:  S Baskar; S Ostrand-Rosenberg; N Nabavi; L M Nadler; G J Freeman; L H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

Review 9.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

10.  Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.

Authors:  J L Schultze; A A Cardoso; G J Freeman; M J Seamon; J Daley; G S Pinkus; J G Gribben; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.